1.6 million UK adults used weight loss drugs in past year
An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according […]
An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according […]
New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings will be presented at […]
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that […]
Less than half of England has access to tirzepatide (Mounjaro) through their GP, despite the NHS roll-out of the weight-loss jab officially starting over two months ago, an […]
Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity […]
Simultaneous treatment with tirzepatide and menopause hormone therapy results in greater weight loss in postmenopausal women who are overweight or obese than tirzepatide monotherapy, researchers reported on July […]
A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an […]
Pharmacist Deborah Evans runs a weight-management clinic at Remedi Health in Winchester. She has helped many people to lose weight and improve their health using the GLP-1 receptor […]
A meta- analysis of studies evaluating the efficacy and safety of various glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for treating obesity in adults without diabetes, suggests […]
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a […]
All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced […]
Treatment with semaglutide and tirzepatide led to significant weight loss and improved blood sugar control in overweight or obese patients with type 1 diabetes (T1D). Researchers reported this […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.